|
1.
|
|
3 p, 1.3 MB |
Vaccine hesitancy and access to psoriasis care during the -19 pandemic : findings from a global patient-reported cross-sectional survey
/
Bechman, Katie (King's College London) ;
Cook, Emma S. (King's College London) ;
Dand, Nick (Health Data Research UK) ;
Yiu, Zenas Z.N. (The University of Manchester) ;
Tsakok, Teresa (King's College London) ;
Meynell, Freya (King's College London) ;
Coker, Bolaji (King's College London) ;
Vincent, Alexandra (King's College London) ;
Bachelez, Hervé (Université de Paris) ;
Barbosa, Ines (King's College London) ;
Brown, Matthew A. (King's College London) ;
Capon, Francesca (King's College London) ;
Contreras, Claudia R. (Universidad Nacional de Asuncion) ;
De La Cruz, Claudia (Clinica Dermacross) ;
Di Meglio, Paola (King's College London) ;
Gisondi, Paolo (University of Verona) ;
Jullien, Denis (Groupe de recherche sur le psoriasis (GrPso) de la Société Française de dermatologie) ;
Kelly, Jade (NIHR Manchester Biomedical Research Centre) ;
Lambert, Jo (Ghent University) ;
Lancelot, Camille (International Federation of Psoriasis Associations) ;
Langan, Sinead M. (London School of Hygiene and Tropical Medicine) ;
Mason, Kayleigh J. (Keele University) ;
McAteer, Helen (The Psoriasis Association) ;
Moorhead, Lucy (King's College London) ;
Naldi, Luigi (Centro Studi GISED) ;
Norton, Sam (King's College London) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Spuls, Phyllis I. (Amsterdam UMC. University Medical Center) ;
Torres, Tiago (Centro Hospitalar do Porto) ;
Urmston, Dominic (The Psoriasis Association) ;
Vesty, Amber (The Psoriasis Association) ;
Warren, Richard B. (NIHR Manchester Biomedical Research Centre) ;
Waweru, Hoseah (International Federation of Psoriasis Associations) ;
Weinman, John (King's College London) ;
Griffiths, Christopher E.M. (NIHR Manchester Biomedical Research Centre) ;
Barker, Jonathan N. (King's College London) ;
Smith, Catherine H. (King's College London) ;
Galloway, James B. (King's College London) ;
Mahil, Satveer K. (King's College London) ;
Universitat Autònoma de Barcelona
2022 -  10.1111/bjd.21042
British journal of dermatology, Vol. 187 (may 2022) , p. 254-256
|
|
|
2.
|
|
|
3.
|
|
24 p, 525.4 KB |
Elevating the Standard of Care for Patients with Psoriasis : 'Calls to Action' from Epicensus, a Multistakeholder Pan-European Initiative
/
Koren, Jan (EUROPSO, Polzela, Slovenia) ;
Lambert, Jo (Ghent University) ;
Thomsen, Simon F. (University of Copenhagen) ;
McAteer, Helen (Psoriasis Association) ;
Fabbrocini, Gabriella (University of Naples Federico II) ;
Corazza, Valeria (Italian Psoriatic Association Friends of the Corazza Foundation) ;
Jullien, Denis (Lyon-1 University) ;
Augustin, Matthias (University Medical Center Hamburg-Eppendorf) ;
Warren, Richard B. (University of Manchester) ;
de Rie, Menno A. (University of Amsterdam) ;
Lazaridou, Elizabeth (Aristotle University School of Medicine) ;
Puig Sanz, Lluís (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Guillevin, Loïc (Université Paris Descartes) ;
Grosser, Marius (German Psoriasis Association) ;
Boehncke, Wolf-Henning (University of Geneva) ;
Universitat Autònoma de Barcelona
Despite advances in treatment options and the management of patients with psoriasis, considerable unmet needs remain. Our objective was to identify ways to elevate the standard of care for patients with psoriasis by combining the perspectives of three important stakeholders: patients, clinicians and payors, and define 'Calls to Action' designed to achieve the identified changes. [...]
2022 - 10.1007/s13555-022-00846-3
Dermatology and Therapy, december 2022, p. 1-24
|
|
|
4.
|
|
15 p, 6.5 MB |
Autochthonous and imported tegumentary leishmaniasis in Catalonia (Spain) : Aetiological evolution in the last four decades and usefulness of different typing approaches based on biochemical, molecular and proteomic markers
/
Fernández-Arévalo, Anna (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Ballart, Cristina (Barcelona Institute for Global Health (ISGlobal)) ;
Muñoz-Basagoiti, Jordana (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Basarte, Leire (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Lobato, Gonzalo (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Arnau, Albert (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Abras, Alba (Laboratori d'Ictiologia Genètica. Departament de Biologia. Universitat de Girona) ;
Tebar, Silvia (Universitat de Barcelona. Departament de Biologia, Sanitat i Medi Ambient) ;
Llovet, Teresa (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ;
Lami, Patrick (National Reference Centre for Leishmaniasis. University Hospital Centre of Montpellier. University of Montpellier) ;
Pratlong, Francine (National Reference Centre for Leishmaniasis. University Hospital Centre of Montpellier. University of Montpellier) ;
Alsina, Mercè (Hospital Clínic i Provincial de Barcelona. Servei de Dermatologia. Universitat de Barcelona. Departament de Medicina) ;
Roé Crespo, Esther (Institut d'Investigació Biomèdica Sant Pau) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Muñoz-Batet, Carmen (Institut d'Investigació Biomèdica Sant Pau) ;
Gállego, Montserrat (Barcelona Institute for Global Health (ISGlobal)) ;
Universitat Autònoma de Barcelona
Leishmaniasis is a transmissible disease caused by Leishmania protozoa. Spain is endemic for both visceral and cutaneous leishmaniasis, the autochthonous aetiological agent being Leishmania infantum. [...]
2022 - 10.1111/tbed.14107
Transboundary and Emerging Diseases, Vol. 69 Núm. 3 (may 2022) , p. 1404-1418
|
|
|
5.
|
|
11 p, 491.7 KB |
Ixekizumab Citrate-Free Formulation : Results from Two Clinical Trials
/
Chabra, S. (Texas Arthritis Center) ;
Gill, B.J. (Complete Dermatology) ;
Gallo, G. (Eli Lilly and Company) ;
Zhu, D. (Eli Lilly and Company) ;
Pitou, C. (Eli Lilly and Company) ;
Payne, C.D. (Eli Lilly and Company) ;
Accioly, A. (Eli Lilly and Company) ;
Puig Sanz, Lluís (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Introduction: Subcutaneous (SC) injection is a common route of drug administration; however, injection site pain (ISP) might create a negative patient experience. We evaluated ISP, bioequivalence, and overall safety of the citrate-free (CF) formulation of ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A. [...]
2022 - 10.1007/s12325-022-02126-0
Advances in Therapy, Vol. 39 Núm. 6 (june 2022) , p. 2862-2872
|
|
|
6.
|
|
27 p, 2.6 MB |
Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents : Part 2 - Management of Special Populations, Patients With Comorbid Conditions, and Risk Actualización práctica de las recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Parte 2 «Manejo de poblaciones especiales, pacientes con comorbilidad y gestión del riesgo»
/
Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Puig Sanz, Lluís (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Belinchón, Isabel (Departamento de Dermatología. Hospital General Universitario de Alicante-ISABIAL- Universidad Miguel Hernández de Elche) ;
Salgado-Boquete, L. (Departamento de Dermatología. Complejo Hospitalario Universitario de Pontevedra) ;
del Alcázar Viladomiu, Elena (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Lencina, J.J.A. (Servicio de Dermatología. Hospital Universitario Vega Baja) ;
Moreno-Ramírez, David (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
De la Cueva, Pablo (Servicio de Dermatología. Hospital Universitario Infanta Leonor. Universidad Complutense de Madrid) ;
Universitat Autònoma de Barcelona
Background and objectives: Since its inception, the Psoriasis Group (GPs) of the Spanish Academy of Dermatology and Venereology (AEDV) has worked to continuously update recommendations for the treatment of psoriasis based on the best available evidence and incorporating proposals arising from and aimed at clinical practice. [...]
2022 - 10.1016/j.ad.2022.01.024
Actas Dermo-Sifiliograficas, Vol. 113 Núm. 6 (junio 2022) , p. 583-609
|
|
|
7.
|
|
|
8.
|
|
9 p, 2.1 MB |
Effect of Hepatitis E Virus RNA Universal Blood Donor Screening, Catalonia, Spain, 2017-2020
/
Bes, M. (Banc de Sang i Teixits) ;
Costafreda Salvany, Maria Isabel (Banc de Sang i Teixits) ;
Riveiro-Barciela, M. (Hospital Universitari Vall d'Hebron) ;
Piron, M. (Banc de Sang i Teixits) ;
Rico, A. (Banc de Sang i Teixits) ;
Quer, J. (Hospital Universitari Vall d'Hebron) ;
Puig Sanz, Lluís (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Sauleda, S. (Banc de Sang i Teixits)
Hepatitis E virus (HEV) is the major cause of acute viral hepatitis in several countries in Europe. HEV is acquired mainly by consumption of contaminated pork but can also be transmitted through blood transfusion. [...]
2022 - 10.3201/eid2801.211466
Emerging Infectious Diseases, Vol. 28 Núm. 1 (january 2022) , p. 157-165
|
|
|
9.
|
|
18 p, 951.7 KB |
Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis : A Network Meta-Analysis
/
Armstrong, April W (Department of Dermatology. Keck School of Medicine. University of Southern California) ;
Soliman, A.M. (AbbVie. Inc.) ;
Betts, K.A. (Analysis Group. Inc.) ;
Wang, Y. (Analysis Group. Inc.) ;
Gao, Y. (Analysis Group. Inc.) ;
Stakias, V. (AbbVie. Inc.) ;
Puig Sanz, Lluís (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Universitat Autònoma de Barcelona
Introduction: The long-term benefit-risk profiles of licensed and investigational treatments for moderate-to-severe plaque psoriasis have not been fully characterized. Methods: Randomized controlled trials (RCTs) of licensed and investigational treatments for moderate-to-severe plaque psoriasis were identified through a systematic literature review through 2 May 2021. [...]
2022 - 10.1007/s13555-021-00647-0
Dermatology and Therapy, Vol. 12 Núm. 1 (january 2022) , p. 167-184
|
|
|
10.
|
|
9 p, 823.5 KB |
The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain
/
Maravilla-Herrera, Paulina (Weber) ;
Merino, María (Weber) ;
Alfonso Zamora, Santiago (Acción Psoriasis) ;
Balea Filgueiras, Jesús (Complejo Hospitalario Universitario de Ferrol) ;
Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Delgado Sánchez, Olga (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Dolz Sinisterra, Francisco (Hospital Universitari Doctor Peset (València)) ;
García-Ruiz, Antonio (Universidad de Málaga) ;
Herranz Pinto, Pedro (Hospital Universitario La Paz (Madrid)) ;
Manfredi, Antonio (Acción Psoriasis) ;
Martínez Olmos, José (Escuela Andaluza de Salud Pública (EASP)) ;
Morales de los Ríos Luna, Paloma (Hospital General Universitario Gregorio Marañón) ;
Puig Sanz, Lluís (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Ros Abarca, Sandra (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Hidalgo, Álvaro (Fundación Weber) ;
Universitat Autònoma de Barcelona
Psoriasis is a chronic disease involving the skin, which significantly impacts the quality of life. Disease severity and treatment efficacy (i. e. , response) are assessed through the Psoriasis Area and Severity Index (PASI). [...]
2023 - 10.3389/fpubh.2023.1000776
Frontiers in Public Health, Vol. 11 (january 2023)
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
